Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report
Item
Click for External Resource*
Click to read full article*
*The link above may share a zip file (.zip) hosted on repository.netecweb.org. Zip files will download automatically.
*All other links are external and will open in a new window. If you click an external link, you are leaving the NETEC site, and we do not maintain, review, or endorse these materials. See our terms of use.
Item Type
PublicationTerms of Use
By accessing these materials you are agreeing to our terms of use, which may be found here: Terms of Use.
Title
Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report
Subject
Description
BNT162b2 is a nucleoside-modified RNA vaccine expressing the full-length prefusion spike glycoprotein (S) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In a randomized, placebo-controlled clinical trial involving approximately 44,000 participants, immunization conferred 95% efficacy against coronavirus disease 2019 (Covid-19).
Date
2021-02-17
Type
Citation
Liu, Yang, Jianying Liu, Hongjie Xia, Xianwen Zhang, Camila R. Fontes-Garfias, Kena A. Swanson, Hui Cai, Ritu Sarkar, Wei Chen, Mark Cutler, David Cooper, Scott C. Weaver, Alexander Muik, Ugur Sahin, Kathrin U. Jansen, Xuping Xie, Philip R. Dormitzer, and Pei-Yong Shi. 2021. "Neutralizing Activity of BNT162b2-Elicited Serum — Preliminary Report." New England Journal of Medicine.
Accessibility
Free online on NEJM.
Was this resource helpful?